News
July 22, 2021
REZUROCKTM Available From Onco360
REZUROCKTM (belumosudil) tablets approved to treat adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of therapy
June 4, 2021
LUMAKRASTM (Sotorasib) Now Approved
LUMAKRAS (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
June 1, 2021
ALUNBRIG® Available From Onco360
ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)
March 15, 2021
Onco360 Selected as Partner for FOTIVDA
Onco360® Selected as Specialty Pharmacy Partner for FOTIVDA® (tivozanib)
February 8, 2021
TG Therapeutics & Onco360 Partner for Ukoniq Launch
UKONIQ™ (umbralisib) Now Approved by the FDA; Onco360® Selected as Exclusive Specialty Pharmacy Partner
December 17, 2020
Help Us Support Feeding America
Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.
June 22, 2020
Second indication for Tazverik™
TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.
May 13, 2020
RETEVMO™ (selpercatinib)
Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.
April 20, 2020
Tukysa™ (tucatinib)
Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.
April 13, 2020
Koselugo (selumetinib)
Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO™ (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.